Current Issue - July 2011, Volume 5, Issue No. 2

1. Lin JH, Russell G, Gertz B. Pharmacokinetics of alendronate: an overview. Int J Clin Pract 1999; 101(Suppl): 18-26.
2. Sharpe M, Noble S, Spencer CM. Alendronate: An update of its use in osteoporosis. Drugs 2001; 61(7): 999-1039.
3. Boonen S, Laan RF, Barton IP, Watts NB. Effect of osteoporosis treatments on risk of non-vertebral fractures: Review and metaanalysis of intention-to-treat studies. Osteoporos Int 2005; 16(10): 1291-8.
4. Nguyen ND, Eisman JA, Nguyen TV. Anti-hip fracture efficacy of biophosphonates: A Bayesian analysis of clinical trials. J Bone Miner Res 2006; 21(2): 340-9.
5. Holder KK, Kerley SS. Alendronate for fracture prevention in postmenopause. Am Fam Physician 2008; 78(5): 579-81.
6. Camacho PM, Lopez NA. Use of biochemical markers of bone turnover in the management of postmenopausal osteoporosis. Clin Chem Lab Med 2008; 46(10): 1345-57.
7. Soontrapa S, Soontrapa S, Bunyaratavej N. Serum concentration of undercarboxylated osteocalcin and the risk of osteoporosis in Thai elderly women. J Med Assoc Thai 2005; 88(Suppl 5): S29-32.
8. Garnero P. Biomarkers for osteoporosis management: Utility in diagnosis, fracture risk prediction and therapy monitoring. Mol Diagn Ther 2008; 12(3): 157-70.
9. Zikan V, Stepan JJ. Marked reduction of bone turnover by alendronate attenuates the acute response of bone resorption marker to endogenous parathyroid hormone. Bone 2009; 44(4): 634-8.
10. Chailurkit LO, Jongjaroenprasert W, Rungbunnapun S, Ongphiphadhanakul B, Sae-tung S, Rajatanavin R. Effect of alendronate on bone mineral density and bone turnover in Thai postmenopausal osteoporosis. J Bone Miner Metab 2003; 21(6): 421-7.
11. Chailurkit LO, Aunphongpuwanart S, Ongphiphadhanakul B, Jongjaroenprasert W, Sae-tung S, Rajatanavin R. Efficacy of intermittent low dose alendronate in Thai postmenopausal osteoporosis. Endocr Res 2004; 30(1):29-36.
12. Bunyaratavej N. Practical experience in some aspects of bone markers. J Med Assoc Thai 2009; 92(Suppl5): S116-20.
13. Bunyaratavej N, Kitimanon N, Boonthitikul S. Study of the level of biochemical bone markers: NMID osteocalcin and bone resorptive marker (beta CTx) in Thai women. J Med Assoc Thai 2001; 84(Suppl 2): S560-5.
14. Biswas PN, Wilton LV, Shakir SA. Pharmacovigilance study of alendronate in England. Osteoporos Int 2003; 14(6): 507-14.
15. Watts N, Freedholm D, Daifotis A. The clinical tolerability profile of alendronate. Int J Clin Pract 1999; 101(Suppl): 51-61.
16. Dansereau RJ, Crail DJ, Perkins AC. In vitro disintegration studies of weekly generic alendronate sodium tablets (70 mg) available in the US. Curr Med Res Opin 2009; 25(2): 449-52.
17. Porras AG, Holland SD, Gertz BJ. Pharmacokinetics of alendronate. Clin Pharmacokinet 1999; 36(5): 315-28.
18. Alendronate monograph. USP 33, NF 28. Available at URL:http://www.uspnf.com
19. Dansereau RJ, Crail DJ, Perkins AC. In vitro disintegration and dissolution studies of once-weekly copies of alendronate sodium tablets (70 mg) and in vivo implications. Curr Med Res Opin 2008; 24(4): 1137-45.
20. Grima DT, Papaioannou A, Airia P, Ioannidis G, Adachi JD. Adverse events, bone mineral density and discontinuation associated with generic alendronate among postmenopausal women previously tolerant of brand alendronate: a retrospective cohort study. BMC Musculoskelet Disord 2010; 11: 68.
21. Bunyaratavej N. Bisphosphonate in general view. Bone forum 2011. Bangkok: Concept Medicus 2011: 33-41.

Abstract   |   Reference